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ABSTRACT
Although selected older adults with acute
myeloid leukemia can benefit from intensive
therapies, recent evidences support the use of
lower-intensity therapies (hypomethylating
agents or low-dose cytarabine) in most of
these patients and emphasize the importance
of tolerability and quality of life. Individualized
approaches to treatment decision-making
beyond consideration of chronologic age alone
should therefore be considered. One promising
strategy is to combine low-intensity treatments
with novel agents.
Keywords: Acute myeloid leukemia;
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INTRODUCTION
Acute myeloid leukemia (AML) occurs mainly
in patients aged 65 years or older. Median age
at diagnosis ranges between 68 and 72 years,
with approximately one-third of patients aged
75 years or older [1]. There is currently no
consensus regarding optimal therapeutic
strategy for older adults with AML, who are
generally defined as those aged 60 years or
older [2, 3]. Intensive chemotherapy has
demonstrated a survival advantage over
supportive care [2]. However, due to
comorbid conditions and disease features,
concerns regarding efficacy and toxicity have
resulted in the ineligibility of many older
patients with AML for this type of treatment
[4]. Prognostic models have been developed to
determine which older adults are likely to
benefit from specific therapies [5–7]. However,
these algorithms are not always easily
applicable in daily clinical practice and each
model relies on chronological age as a
surrogate for measurable patient-specific
factors that vary among individuals of similar
age. Furthermore, even in patients who can
tolerate intensive therapy, outcomes remain
poor. Recently published single-center data
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showed a complete remission (CR) rate of 48%
after intensive chemotherapy, with median
overall survival of 7.4 months and 5-year
overall survival of only 10% [8]. Over the
last decades, there has been little progress in
improving prognosis for patients aged
60 years or older, resulting in unmet
needs necessitating novel therapeutic
strategies [9].
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by the
author.
AGING AND AML
Acute myeloid leukemia (AML) is a different
disease in older patients. Aging is a complex
process influenced by genetic variables as well
as environmental factors [10]. Leukemia cells
are more likely to be CD34?CD33? which
correlates with poor outcome [11], to have
more poor-risk karyotypes [complex
karyotypes, chromosome 3 abnormalities,
abnormalities of 11q, total or partial
monosomy 7, total or partial monosomy 5]
and fewer favorable-risk cytogenetics [t(8;21),
inv(16) or t(16;16), or t(15;17)] [12]. Older
patients have shown a higher probability of
RAS (Rat sarcoma), SRC (Sarcoma), and tumor
necrosis factor pathway activation than
younger patients, which may contribute to
their poorer survival [13]. Leukemia blasts
have higher expression of the MRD1 gene,
responsible for drug efflux and resistance [14],
and are less likely to undergo apoptosis [15].
Poor outcome in older patients with AML is
also correlated with impaired functional and
nutritional status, presence of comorbidities,
and mental health leading to loss of
autonomy after chemotherapy [16–18].
INTENSIVE THERAPY IN ELDERLY
PATIENTS WITH AML
Despite recent improvements, median survival
in clinical trials using intensive chemotherapy
remains less than 1 year [19]. Although older
patients enrolled in clinical trials have adequate
performance status, they are less likely than
younger adults to achieve CR and remain
relapse-free. Inversely, early death rate is
higher [19, 20]. Standard induction
chemotherapy remains a combination of
intermediate-dose cytarabine with an
anthracycline administered for 7 and 3 days
(‘7 ? 3’), respectively. This approach has been
shown to improve survival as compared with
supportive care only [21]. Different induction
regimens (including anthracycline substitution,
addition of hematopoietic growth factors,
modulation of multidrug resistance, or
addition of a novel agent) have been proposed
but have not consistently improved efficacy
(reviewed in [17]). However, improved
outcomes have been reported in a subset of
patients aged 60–65 years receiving higher dose
of daunorubicin (90 mg/m2) when compared to
a dosage of 45 mg/m2 [22], but this was not true
if compared to the dosage of 60 mg/m2 [23].
Improved outcomes have also been reported in
patients receiving low-dose gemtuzumab
ozogamicin combined with a standard
induction chemotherapy [24, 25]. CPX-351, a
liposomal formulation of a synergistic 5:1 molar
ratio of cytarabine and daunorubicin, was
studied in a randomized phase 2 trial in older
patients with AML and showed improved
survival for CPX-351 compared with ‘7 ? 3’
chemotherapy [26]. Optimal duration or
intensity of consolidation therapy in older
patients remains unclear, although an
association has been established between dose-
intensity and increased toxicity [27]. Overall, up
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to 20% of older adults who achieved CR,
enrolled in intensive chemotherapy trials, do
not receive any consolidation therapy. Several
studies have indicated that subsequent cycles of
intensive chemotherapy following achievement
of CR offered no benefit to patients [27, 28]. The
introduction of reduced-intensity conditioning
regimens has resulted to an increased use of
hematopoietic stem cell transplantation (HSCT)
in patients aged 60–70 years. Although HSCT
appears feasible for selected patients, it remains
unclear whether this procedure is better than
more conventional approaches in terms of
survival and quality of life [29, 30]. However,
analyses of the SEER database clearly show
longer overall survival in patients who
received allogeneic HSCT [4].
FITNESS AND INTENSIVE CARE
ELIGIBLITY
Older patients with favorable prognostic AML
(acute promyelocytic leukemia, core binding
factor AML, and NPM1-mutated AML) can be
cured with intensive chemotherapy [2, 31].
Therefore, the issue is to identify the elderly
patients with AML who could benefit from
intensive chemotherapy. Prognostic models
have been developed from clinical trial data to
improve outcome prediction for older patients
with AML [3, 5–7]. Each of these algorithms
provides useful information, but primarily
explores the heterogeneity of tumor biology
and relies on chronological age as a surrogate
for measurable patient-specific factors. The one
most consistent factor with clinical outcome
after intensive chemotherapy was cytogenetics.
Poor performance status can be related to the
disease itself and should not be considered as a
limiting factor for intensive chemotherapy. In
multivariate analyses, poor outcome or early
death were significantly correlated with poor
cytogenetic and not with age or comorbidities
[32]. Older patients with AML, particularly
those older than age 70 years, have specific
needs. The traditional oncology evaluation is
often not adequate and will fail to uncover
specific problems. Therefore, there has been
increasing debate regarding the appropriate
therapeutic decision-making for the geriatric
patient population, which should be offered
therapy to prolong both survival and quality of
life. Clinical tools have been developed to
predict grade 3–4 chemotherapy toxicity [33].
The chemotherapy risk assessment scale for
high-age patients (CRASH) score can
distinguish several risk levels of severe
chemotherapy toxicity [34] and should be
incorporated into clinical trials.
HYPOMETHYLATING AGENTS
IN ELDERLY PATIENTS WITH AML
For many older patients, the risk of treatment-
related mortality may outweigh the potential
transient benefits of intensive chemotherapy.
Lower-intensity regimens have then been
proposed. In this setting, low-dose cytarabine
has demonstrated improved survival among
patients considered not fit for intensive
treatment compared with supportive care
alone, and is usually regarded as the standard
therapy for this type of patient, although fitness
has not clearly been defined [35]. However,
outcomes with low-dose cytarabine are
generally poor with a median survival time of
only 4 months. Recent studies have shown that
gene hypermethylation is widespread in
patients with AML and is implicated in
leukemogenesis [36]. Hypomethylating agents
(decitabine and azacitidine) may have the
potential to improve survival and quality of
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life in elderly patients and have been assessed in
phase 3 studies [37–39]. The DACO-016 study
(ClinicalTrials.gov number, NCT00260832) has
compared the efficacy and safety of decitabine
(20 mg/m2/day for 5 days every 4 weeks) versus
best supportive care or low-dose cytarabine
(20 mg/m2/day for 10 days every 4 weeks) in
485 patients ineligible for intensive
chemotherapy [37]. While the first analysis
demonstrated a non-significant trend towards
improved overall survival in the decitabine arm,
an unplanned ad hoc analysis performed 1 year
later following 446 deaths showed a significant
difference between the two arms of
randomization (median overall survival: 7.7
versus 5 months; P = 0.037) [37]. Following
this trial, decitabine was approved by the
European Medicines Agency (EMA) for the
treatment of AML in patients aged 65 years or
older who are not candidates for intensive
chemotherapy, but not by the US Food and
Drug Agency (FDA). The AZA-001 trial
(ClinicalTrials.gov number, NCT00071799)
compared the efficacy and safety of azacitidine
with conventional care regimens (best
supportive care, low-dose cytarabine, intensive
chemotherapy) in 358 patients with
predominantly intermediate-2/high-risk
myelodysplastic syndromes [38]. However, 113
patients of this series were with AML, when
considering the World Health Organization
(WHO) classification (20–30% blasts). In these
patients, a significant difference in overall
survival favoring azacitidine versus
conventional care regimens was detected
(median overall survival: 24.5 versus
16.0 months; P = 0.005). Furthermore, more
patients transfusion-dependent at baseline
achieved transfusion independence with
azacitidine (41% versus 18%; P = 0.04). Based
on this analysis, azacitidine has become
established as a treatment option for patients
with 20–30% leukemia cells in bone marrow,
who are ineligible for intensive chemotherapy.
In the AZA-AML-001 trial (ClinicalTrials.gov
number, NCT01074047), 480 patients with
more than 30% leukemia cells in bone marrow
were randomized to receive either azacitidine
(75 mg/m2/day for 7 days every 4 weeks) or
conventional care regimens [39]. Median
overall survival was 10.4 months in the
azacitidine arm compared to 6.5 months in
the conventional care regimens group
(P = 0.08). However, when censoring patients
at the start of the subsequent AML therapy, the
analysis showed a longer median overall
survival in patients receiving azacitidine
(median overall survival: 12.1 months versus
6.9 months; P = 0.019) [39]. SGI-110, a
dinucleotide of decitabine and
deoxyguanosine with distinctive
pharmacokinetic properties that allow a longer
half-life and more extended decitabine
exposure, is currently being investigated in
older patients with AML. Response rate was
53% in a phase 2 first-line therapy in older
patients with AML [40].
NOVEL TREATMENTS
IN DEVELOPMENT FOR AML
Novel agents used as single-agent or in
combination (Table 1) are under investigation
for the treatment older patients with newly
diagnosed AML. The anti-CD33-conjugated
cytotoxic gemtuzumab ozogamicin, the
nucleoside analogue prodrug clofarabine, and
the farnesyltransferase inhibitor tipifarnib were
both investigated in combination with low-dose
cytarabine in a ‘pick-a-winner’ trial design.
Combined data of gemtuzumab ozogamicin
plus low-dose cytarabine demonstrated an
improved response rate compared with low-
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dose cytarabine alone (30% versus 17%;
P = 0.006), but no difference in terms of
overall survival [41]. A comparison of
clofarabine versus low-dose cytarabine also
showed a higher response rate with
clofarabine, but no difference in overall
survival [42], while the addition of tipifarnib
to low-dose cytarabine was found to have no
effect on response or survival [43]. In
combination with low-dose cytarabine
compared with single-agent clofarabine, CR
rate was higher in the first group (67% versus
31%; P = 0.012). Median overall survival was
11.4 months versus 5.8 months (P = 0.10),
while median event-free survival was 7.1
versus 1.7 months (P = 0.04) [44]. In
combination with azacitidine, gemtuzumab
ozogamicin CR rates of 44% and 35% for
patients with good-risk or poor-risk AML,
respectively [45]. Sapacitabine, a nucleoside
analogue prodrug, is currently under
investigation in combination with decitabine
(ClinicialTrials.gov number, NCT01303796).
Preliminary data demonstrated response in
9/25 patients aged C70 years with newly
diagnosed AML [46]. Volasertib, a cell cycle
kinase inhibitor, is currently under phase 3
investigation in combination with low-dose
cytarabine versus low-dose cytarabine alone
(ClinicalTrials.gov number, NCT01721876). In
a phase 2, volasertib plus low-dose cytarabine
has shown improved efficacy versus low-dose
cytarabine with CR rates of 31% versus 13%
(P = 0.05). Median overall survival was also
prolonged (8 versus 5.2 months; P = 0.047)
[47]. The aurora kinase B inhibitor barasertib is
under investigation in combination with low-
dose cytarabine (ClincalTrials.gov number,
NCT00952588). Phase 1 evaluation of this
combination showed a response rate of 45%
[48]. While the first part of the phase 3 trial has
been reported [49], the clinical development of
barasertib in AML has been discontinued. A
clinical trial combining lenalidomide plus
azacitidine is currently recruiting patients
(ClinicalTrials.gov number, NCT01358734). A
phase 1/2 with this combination showed 41%
of CR, and a median overall survival of 20 weeks
[50]. Vorinostat in combination with
azacitidine is currently under investigation
(ClinicalTrials.gov number, NCT00948064).
Although not limited to older patients,
available data from phase 2 showed 30% of CR
and 7 months of median overall survival with
this combination [51]. Two trials evaluating
decitabine combinations are ongoing: One with
tosedostat, an aminopeptidase inhibitor
(ClinicalTrials.gov number, NCT01567059)
and one with bordezomib, a proteasome
inhibitor (ClinicalTrials.gov number,
NCT01420926). Preliminary data with this last
combination demonstrated 50% of response
[52]. Older patients with FLT3 mutant AML
should ideally be considered for therapy
incorporating a FLT3 inhibitor. The addition
of sorafenib, an oral inhibitor of multiple
tyrosine kinases including FLT3, to upfront
intensive chemotherapy was not beneficial
[53]. However, a phase 2 trial of sorafenib
combined with azacitidine in FLT3 mutant
AML of all ages resulted in an overall response
rate of 46% [54]. Based on the discovery of
recurrent somatic point mutations in the
isocitrate dehydrogenase (IDH1) gene, and its
isoform IDH2, small molecule inhibitors are
being developed to inhibit the neomorphic
enzyme, which activity results in the
accumulation of the metabolite
2-hydroxyglutarate. Preliminary results of a
phase 1 dose-escalation study with AG-221, an
oral IDH2 inhibitor, showed good tolerance and
no-limiting toxicities [55]. The tandem
bromodomain (BRD)-containing family of
transcriptional regulators, known as
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bromodomains and extraterminal (BET)
proteins, has emerged as major epigenetic
regulators of proliferation and differentiation.
In AML, the inhibition of BRD4 led to cell cycle
arrest and apoptosis. A phase 1 clinical trial




Treatment recommendations for elderly
patients with AML need to be individualized.
Hypomethylating agents may provide an
exciting new approach to the treatment of
elderly patients potentially as monotherapy,
and mainly in combination regimens with
other agents. Although CR rate was higher
with intensive chemotherapy, there was a
trend for lower early mortality with epigenetic
therapy. More accurate biomarkers are needed
to better identify patients who may or may not
benefit from intensive chemotherapy. In
younger adults, molecular profiling of
aberrations such as NPM1 and DNMT3A
mutations and MLL translocations could
identify patients who are most likely to benefit
from a certain treatment or dose intensity [57,
58]. However, in multiple studies, patients aged
60 years and older with NPM1-mutated AML
have far superior outcomes and survival after
intensive therapy compared with any other
treatment modality [59–61]. Presence of the
FLT3 mutation was associated with a worse
outcome, regardless of NPM1 status [62]. In
order to avoid toxicities, hematologists should
collaborate more and more with geriatricians to
identify clues of vulnerability in elderly patients
through the study of functional physical,
physiological, cognitive, social and
psychological parameters [63]. It appears that
chronological age may not be a robust predictor
of outcome after accounting for function,
comorbidities, and symptoms [64]. These
comprehensive geriatric assessments were
shown more specific than the screening tool
G8, which is the most studied screening tool
applied in geriatric oncology [65]. Indeed,
systematic measurement of patient-specific
factors can help discriminate among fit,
vulnerable, and frail patients for a given
treatment. Studies have shown that assessment
of self-reported activities of daily living and
measured physical performance are predictive
of survival after accounting for performance
status [66, 67]. Better understanding of specific
patient vulnerabilities are under evaluation and
may help to defined adaptive clinical trial
design for specific patient subgroups [68, 69].
The Townsend index, which measures material
deprivation based on unemployment, car
ownership, home ownership and
overcrowding, was found to be significantly
increased in older patients and correlated with
survival [70]. Furthermore, a correlation has
recently been confirmed between the use of
potentially inappropriate medication,
polypharmacy (defined as the concurrent use
of an excessive number of drugs), and increased
comorbidities [71]. Polypharmacy should
therefore be a critical component of geriatric
evaluation [72]. An important issue remains the
lack of a prospective definition of the so called
‘unfit’ population. Hypomethylating agents or
low-dose cytarabine can serve as backbone low-
intensity treatments with which novel therapies
could be combined. Decision-making should be
determined through patient-centered
discussions and taken with the aim to keep an
accurate balance between efficacy of therapy
and avoidance of a decreased quality of life and
loss of autonomy feared by elderly patients and
their families. Inclusion in clinical trials will
furnish some guarantee for quality of treatment,
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while offering the opportunity to contribute to
therapeutic progress [73].
ACKNOWLEDGMENTS
No funding or sponsorship was received for
publication of this article. The named author
meet the International Committee of Medical
Journal Editors (ICMJE) criteria for authorship
for this manuscript, takes responsibility for the
integrity of the work as a whole, and has given
final approval of the version published.
Conflict of interest. Xavier Thomas declares
that he has no conflict of interest.
Compliance with ethics guidelines. This article
is based on previously conducted studies and
does not involve any new studies of human or
animal subjects performed by the author.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution Noncommercial License which
permits any noncommercial use, distribution,
and reproduction in any medium, provided the
original author(s) and the source are credited.
REFERENCES
1. Surveillance, Epidemiology, and End Results
program: SEER Cancer Statistics Review
1975–2009. http://seer.cancer.gov/archive/csr/1975_
2009_pops09/.
2. Juliusson G, Antunovic P, Derolf A, et al. Age and
acute myeloid leukemia: real world data on decision
to treat and outcomes from the Swedish Acute
Leukemia Registry. Blood. 2009;113:4179–87.
3. Kantarjian H, Ravandi F, O’Brien S, et al. Intensive
chemotherapy does not benefit most older patients
(age 70 years and older) with acute myeloid
leukemia. Blood. 2010;116:4422–9.
4. Oran B, Weisdorf DJ. Survival for older patients
with acute myeloid leukemia: a population-based
study. Haematologica. 2012;97:1916–24.
5. Krug U, Ro¨llig C, Koschmieder A, et al. Complete
remission and early death after intensive
chemotherapy in patients aged 60 years or older
with acute myeloid leukaemia: a Web-based
application for prediction of outcomes. Lancet.
2010;376:2000–8.
6. Ro¨llig C, Thiede C, Gramatzki M, et al. A
novelprognostic model in elderly patients with
acute myeloid leukemia: results of 909 patients
entered into the prospective AML96 trial. Blood.
2010;116:971–8.
7. Wheatley K, Brookes CL, Howman AJ, et al.
Prognostic factor analysis of the survival of elderly
patients with AML in the MRC AML11 and LRF
AML14 trials. Br J Haematol. 2009;145:598–605.
8. Kantarjian H, O’Brien S. Questions regarding
frontline therapy of acute myeloid leukemia.
Cancer. 2010;116:4896–901.
9. Alibhai SM, Leach M, Minden MD, Brandwein J.
Outcomes and quality of care in acute myeloid
leukemia over 40 years. Cancer. 2009;115:2903–11.
10. Lopez-Otin C, Blasco MA, Partridge L, Serrano M,
Kroemer G. The hallmarks of aging. Cell.
2013;153:1194–217.
11. Plesa C, Chelghoum Y, Plesa A, et al. Prognostic
value of immunophenotyping in elderly patients
with acute myeloid leukemia: a single-institution
experience. Cancer. 2008;112:572–80.
12. Farag SS, Archer KJ, Mrozek K, et al. Pretreatment
cytogenetics add to other prognostic factors
predicting complete remission and long-term
outcome in patients 60 years of age or older with
acute myeloid leukemia: results from Cancer and
Leukemia Group B 8461. Blood. 2006;108:63–73.
13. Rao AV, Valk PJ, Metzeler KH, et al. Age-specific
differences in oncogenic pathway dysregulation and
anthracycline sensitivity in patients with acute
myeloid leukemia. J Clin Oncol. 2009;27:5580–6.
14. Leith CP, Kopecky KJ, Chen IM, et al. Frequency and
clinical significance of the expression of themultidrug
resistance proteins MDR1/P-glycoprotein, MRP1, and
LRP in acutemyeloid leukemia: a SouthwestOncology
Group study. Blood. 1999;94:1086–99.
15. Garrido SM, Cooper JJ, Appelbaum FR, et al. Blasts
from elderly acute myeloid leukemia patients are
characterized by low levels of culture- and drug-
induced apoptosis. Leuk Res. 2001;25:23–32.
8 Rare Cancers Ther (2015) 3:1–11
16. Deschler B, Ihorst G, Platzbecker U, et al.
Parameters detected by geriatric and quality of life
assessment in 195 older patients with
myelodysplastic syndromes and acute myeloid
leukemia are highly predictive for outcome.
Haematologica. 2013;98:208–16.
17. Klepin H, Rao A, Pardee T. Acute myeloid leukemia
and myelodysplastic syndromes in older adults.
J Clin Oncol. 2014;32:2541–52.
18. Hamaker ME, Prins MC, Stauder R. The relevance of
geriatric assessment for elderly patients with a
haematological malignancy—a systematic review.
Leuk Res. 2014;38:275–83.
19. Appelbaum FR, Gundacker H, Head DR, et al. Age
and acute myeloid leukemia. Blood. 2006;107:
3481–5.
20. Kantarjian H, O’Brien S, Cortes J, et al. Results of
intensive chemotherapy in 998 patients age
65 years or older with acute myeloid leukemia or
high-risk myelodysplastic syndrome. Predictive
prognostic models for outcome. Cancer. 2006;106:
1090–8.
21. Lo¨wenberg B, Zittoun R, Kerkhofs H, et al. On the
value of intensive remission-induction
chemotherapy in elderly patients of 65? years
with acute myeloid leukemia: a randomized phase
III study of the European Organization for Research
and Treatment of Cancer Leukemia Group. J Clin
Oncol. 1989;7:1268–74.
22. Lo¨wenberg B, Ossenkoppele GJ, van Putten W, et al.
High-dose daunorubicin in older patients with
acute myeloid leukemia. N Engl J Med.
2009;361:1235–48.
23. Burnett AK, Russell NH, Hills RK, et al. A
randomised comparison of daunorubicin 90 mg/
m2 vs 60 mg/m2 in AML induction: results from the
UK NCRI AML17 trial in 1206 patients. Blood. 2015;
[Epub ahead of print].
24. Castaigne S, Pautas C, Terre´ C, et al. Effect of
gemtuzumab ozogamicin on survival of adult
patients with de-novo acute myeloid leukaemia
(ALFA-0701): a randomised, open-label, phase 3
study. Lancet. 2012;379:1508–16.
25. Burnett AK, Russell NH, Hills RK, et al. Addition of
gemtuzumab ozogamicin to induction
chemotherapy improves survival in older patients
with acute myeloid leukemia. J Clin Oncol.
2012;30:3924–31.
26. Lancet JE, Cortes JE, Hogge DE, et al. Phase II,
multicenter, randomized, open label trial of CPX-
351 (cytarabine:daunorubicin) liposome injection
versus cytarabine and daunorubicin in patients
with untreated AML 60–75 years of age. Blood.
2014;123:3239–46.
27. Stone RM, Berg DT, George SL, et al. Postremission
therapy in older patients with de novo acute
myeloid leukemia: a randomized trial comparing
mitoxantrone and intermediate-dose cytarabine
with standard-dose cytarabine. Blood.
2001;98:548–53.
28. Gardin C, Turlure P, Fagot T, et al. Postremission
treatment of elderly patients with acute myeloid
leukemia in first complete remission after intensive
induction chemotherapy: results of the multicenter
randomized Acute Leukemia French Association
(ALFA) 9803 trial. Blood. 2007;109:5129–35.
29. Hahn T, McCarthy PL, Hassebroek A, et al.
Significant improvement in survival after
allogeneic hematopoietic cell transplantation
during a period of significantly increased use,
older recipient age, and use of unrelated donors.
J Clin Oncol. 2013;31:2437–49.
30. McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect
of age on outcome of reduced-intensity
hematopoietic cell transplantation for older
patients with acute myeloid leukemia in first
complete remission or with myelodysplastic
syndrome. J Clin Oncol. 2010;28:1878–87.
31. Wetzler M, Mro¨zek K, Kohlschmidt J, et al. Intensive
induction is effective in selected octogenarian acute
myeloid leukemia patients: prognostic significance
of karyotype and selected molecular markers used in
the European LeukemiaNet classification.
Haematologica. 2014;99:308–13.
32. Grimwade D, Walker H, Harrison G, et al. The
predictive value of hierarchical cytogenetic
classification in older adults with acute myeloid
leukemia (AML): analysis of 1065 patients entered
into the United KingdomMedical Research Council
AML11 trial. Blood. 2001;98:1312–20.
33. Hurria A, Togawa K, Mohile SG, et al. Predicting
chemotherapy toxicity in older adults with cancer:
a prospective multicenter study. J Clin Oncol.
2011;29:3457–65.
34. Extermann M, Boler I, Reich RR, et al. Predicting
the risk of chemotherapy toxicity in older patients:
The Chemotherapy Risk Assessment Scale for High-
Age Patients (CRASH) score. Cancer. 2012;118:
3377–86.
35. Burnett AK, Milligan D, Prentice AG, et al. A
comparison of low-dose cytarabine and
hydroxuyurea with or without all-trans retinoic
acid for acute myeloid leukemia and high-risk
myelodysplastic syndrome in patients not
Rare Cancers Ther (2015) 3:1–11 9
considered fit for intensive treatment. Cancer.
2007;109:1114–24.
36. Kroeger H, Jelinek J, Estecio MR, et al. Aberrant CpG
island methylation in acute myeloid leukemia is
accentuated at relapse. Blood. 2008;112:1366–73.
37. Kantarjian HM, Thomas XG, Dmoszynska A, et al.
Multicenter, randomized, open-label, phase III trial
of decitabine versus patient choice, with physician
advice, of either supportive care or low-dose
cytarabine for the treatment of older patients with
newly diagnosed acute myeloid leukemia. J Clin
Oncol. 2012;30:2670–7.
38. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al.
Azacitidine prolongs overall survival compared
with conventional care regimens in elderly
patients with low bone marrow blast count acute
myeloid leukemia. J Clin Oncol. 2010;28:562–9.
39. Dombret H, Seymour JF, Butrym A, et al.
International phase 3 study of azacitidine vs
conventional care regimens in older patients with
newly diagnosed AML with [30% blasts. Blood.
2015; [Epub ahead of print].
40. Kantarjian H, Jabbour E, Yee K, et al. First clinical
results of a randomized phase 2 study of SGI-110, a
novel subcutaneous (SQ) hypomethylating agent
(HMA), in adult patients with acute myeloid
leukemia (AML). Blood. 2013;122:497.
41. Burnett AK, Hills RK, Hunter AE, et al. The addition
of gemtuzumab ozogamicin to low-dose Ara-C
improves remission rate but does not significantly
prolong survival in older patients with acute
myeloid leukaemia: results from the LRF AML 14
and NCRI AML 16 pick-a-winner comparison.
Leukemia. 2013;27:75–81.
42. Burnett AK, Russell NH, Hunter AE, et al.
Clofarabine doubles the response rate in older
patients with acute myeloid leukemia but does
not improve survival. Blood. 2013;122:1384–94.
43. Burnett AK, Russell NH, Culligan D, et al. The
addition of the farnesyl transferase inhibitor,
tipifarnib, to low-dose cytarabine does not
improve outcome for older patients with AML. Br
J Haematol. 2012;158:519–22.
44. Faderl S, Ravandi F, Huang X, et al. A randomized
study of clofarabine versus clofarabine plus low-
dose cytarabine as front-line therapy for patients
aged 60 years or older with acute myeloid leukemia
and high-risk myelodysplastic syndrome. Blood.
2008;112:1638–45.
45. Nand S, Othus M, Godwin JE, et al. A phase 2 trial of
azacitidine and gemtuzumab ozogamicin therapy
in older patients with acute myeloid leukemia.
Blood. 2013;122:3432–9.
46. Ravandi F, Faderl S, Cortes JE, et al. Phase 1/2 study
of sapacitabine and decitabine administered
sequentially in elderly patients with newly
diagnosed AML. Blood. 2011; 118:abstract 3630.
47. Do¨hner H, Lu¨bbert M, Fiedler W, et al. Randomized
phase 2 trial comparing low-dose cytarabine with or
without volasertib in AML patients not suitable for
intensive induction therapy. Blood. 2014;124:
1426–33.
48. Kantarjian HM, Sekeres MA, Ribrag V, et al. Phase I
study assessing the safety and tolerability of
barasertib (AZD1152) with low-dose cytosine
arabinoside in elderly patients with AML. Clin
Lymphoma Myeloma Leuk. 2013;13:559–67.
49. Kantarjian HM, Martinelli G, Jabbour EJ, et al. Stage
1 of a phase 2 study assessing the efficacy, safety,
and tolerability of barasertib (AZD1152) versus low-
dose cytosine arabinoside in elderly patients with
acute myeloid leukemia. Cancer. 2013;119:2611–9.
50. Pollyea DA, Zehnder J, Coutre S, et al. Sequential
azacitidine plus lenalidomide combination for
elderly patients with untreated acute myeloid
leukemia. Haematologica. 2013;98:591–6.
51. Garcia-Manero G, Estey EH, Jabbour E, et al. Final
report of a phase II study of 5-azacitidine and
vorinostat in patients (pts) with newly diagnosed
myelodysplastic syndrome (MDS) or acute
myelogenous leukemia (AML) not eligible for
clinical trials because poor performance and
presence of other comorbidities. Blood. 2011;
118:abstract 608.
52. Blum W, Schwind S, Tarighat SS, et al. Clinical and
pharmacodynamic activity of bortezomib and
decitabine in acute myeloid leukemia. Blood.
2012;119:6025–31.
53. Serve H, Krug U, Wagner R, et al. Sorafenib in
combination with intensive chemotherapy in
elderly patients with acute myeloid leukemia:
results from a randomized, placebo-controlled
trial. J Clin Oncol. 2013;31:3110–8.
54. Ravandi F, Alattar ML, Grunwald MR, et al. Phase 2
study of azacytidine plus sorafenib in patients with
acute myeloid leukemia and FLT-3 internal tandem
duplication mutation. Blood. 2013;121:4655–62.
55. Stein E, Tallman MS, Pollya D, et al. Clinical safety
and activity in a phase I trial AG-221, a first in class,
potent inhibitor of the IDH2-mutant protein in
patients with IDH2 mutant positive advanced
hematologic malignancies. AACR Annual Meeting.
2014; abstract CT103.
10 Rare Cancers Ther (2015) 3:1–11
56. Dombret H, Preudhomme C, Berthon C, et al. A
phase 1 study of the BET-bromodomain inhibitor
OTX015 in patients with advanced acute leukemia.
56th Annual Meeting of the American Society of
Hematology. Blood. 2014; 124: abstract 117.
57. Patel JP, Gonen M, Figueroa ME, et al. Prognostic
relevance of integrated genetic profiling in acute
myeloid leukemia. N Engl J Med. 2012;366:
1079–89.
58. Schlenk RF, Do¨hner K, Krauter J, et al. Mutations
and treatment outcome in cytogenetically normal
acute myeloid leukemia. N Engl J Med.
2008;358:1909–18.
59. Quintas-Cardama A, Ravandi F, Liu-Dumlao T, et al.
Epigenetic therapy is associated with similar
survival compared with intensive chemotherapy
in older patients with newly diagnosed acute
myeloid leukemia. Blood. 2012;120:4840–5.
60. Becker H, Marcicci G, Maharry K, et al. Favorable
prognostic impact of NPM1 mutations in older
patients with cytogenetically normal de novo acute
myeloid leukemia and associted gene- and
microRNA-expression signatures: a Cancer and
Leukemia Group B study. J Clin Oncol.
2010;28:596–604.
61. Daver N, Liu Dumlao T, Ravandi F, et al. Effects of
NPM1 and FLT3 mutations on the outcomes of
elderly patients with acute myeloid leukemia
receiving standard chemotherapy. Clin
Lymphoma Myeloma Leuk. 2013;13:435–40.
62. Scholl S, Theuer C, Scheble V, et al. Clinical impact
of nucleophosmin mutations and Flt3 internal
tandem duplications in patients older than 60 yr
with acute myeloid leukaemia. Eur J Haematol.
2008;80:208–15.
63. Klepin HD, Geiger AM, Tooze JA, et al. The
feasibility of inpatient geriatric assessment for
older adults receiving induction chemotherapy for
acute myelogenous leukemia. J Am Geriatr Soc.
2011;59:1837–46.
64. Sherman AE, Motyckova G, Fega KR, et al. Geriatric
assessment in older patients with acute myeloid
leukemia: a retrospective study of associated
treatment and outcomes. Leuk Res. 2013;37:
998–1003.
65. Dubruille S, Libert Y, Maerevoet M, et al. Prognostic
value of neuro-psychological and biological factors
in clinically fit older patients with hematological
malignancies admitted to receive chemotherapy.
Blood. 2014; 124:abstract 2630.
66. Klepin HD, Geiger AM, Tooze JA, et al. Geriatric
assessment predicts survival for older adults
receiving induction chemotherapy for acute
myelogenous leukemia. Blood. 2013;121:4287–94.
67. Wedding U, Ro¨hrig B, Klippstein A, et al.
Impairment in functional status and survival in
patients with acute myeloid leukaemia. J Cancer
Res Clin Oncol. 2006;132:665–71.
68. Alibhai SM, O’Neill S, Fisher-Schlombs K, et al. A
clinical trial of supervised exercise for adults
inpatients with acute myeloid leukemia (AML)
undergoing induction chemotherapy. Leuk Res.
2012;36:1255–61.
69. Klepin HD, Danhauer SC, Tooze JA, et al. Exercise
for older adult inpatients with acute myelogenous
leukemia: a pilot study. J Geriatr Oncol.
2011;2:11–7.
70. Kristinsson SY, Derolf AR, Edgren G, et al.
Socioeconomic differences in patient survival are
increasing for AML and MM in Sweden. J Clin
Oncol. 2009;27:2073–80.
71. Maggiore RJ, Dale W, Gross CP, et al. Polypharmacy
and potentially inappropriate medication use in
older adults with cancer undergoing
chemotherapy: effect on chemotherapy-related
toxicity and hospitalization during treatment.
J Am Geriatr Soc. 2014;62:1505–12.
72. Flood KL, Carroll MB, Le CV, et al. Geriatric
syndromes in elderly patients admitted to an
oncology-acute care for elders unit. J Clin Oncol.
2006;24:2298–303.
73. Ossenkoppele G, Lo¨wenberg B. How I treat the
older patient with acute myeloid leukemia. Blood.
2015;125:767–74.
Rare Cancers Ther (2015) 3:1–11 11
